First National Bank of Omaha reduced its position in Becton Dickinson and Co (NYSE:BDX) by 2.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,218 shares of the medical instruments supplier’s stock after selling 632 shares during the quarter. First National Bank of Omaha’s holdings in Becton Dickinson and were worth $5,620,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. TRUE Private Wealth Advisors bought a new position in Becton Dickinson and in the 2nd quarter worth $25,000. Allworth Financial LP raised its holdings in Becton Dickinson and by 386.4% in the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 85 shares during the period. Northwest Investment Counselors LLC bought a new position in Becton Dickinson and in the 3rd quarter worth $27,000. Hexavest Inc. bought a new position in Becton Dickinson and in the 2nd quarter worth $28,000. Finally, Lipe & Dalton bought a new position in Becton Dickinson and in the 2nd quarter worth $28,000. Hedge funds and other institutional investors own 84.29% of the company’s stock.
A number of brokerages recently commented on BDX. Wells Fargo & Co decreased their target price on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Wednesday. Piper Jaffray Companies decreased their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Morgan Stanley raised their target price on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $266.09.
In other Becton Dickinson and news, EVP Alexandre Conroy sold 9,829 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total value of $2,506,984.74. Following the sale, the executive vice president now directly owns 16,535 shares of the company’s stock, valued at $4,217,417.10. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,174 shares of company stock worth $8,354,013. 0.12% of the stock is owned by corporate insiders.
BDX traded up $0.06 on Friday, hitting $244.64. The company had a trading volume of 961,860 shares, compared to its average volume of 1,180,223. The company has a market cap of $66.59 billion, a PE ratio of 20.94, a PEG ratio of 1.62 and a beta of 1.09. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $264.74. The company has a quick ratio of 0.67, a current ratio of 1.19 and a debt-to-equity ratio of 0.85. The business’s fifty day simple moving average is $252.19 and its 200 day simple moving average is $246.80.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The company had revenue of $4.58 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the business posted $2.93 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. On average, analysts anticipate that Becton Dickinson and Co will post 12.58 earnings per share for the current fiscal year.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Commodities
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.